Novo Nordisk A/S (NONOF)
| Previous Close | 137.00 |
| Open | 131.84 |
| Bid | 131.21 x 46000 |
| Ask | 133.96 x 47300 |
| Day's Range | 131.33 - 131.84 |
| 52 Week Range | 86.75 - 149.55 |
| Volume | |
| Avg. Volume | 30,973 |
| Market Cap | 597.861B |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | 44.07 |
| EPS (TTM) | 2.98 |
| Earnings Date | Nov 06, 2024 |
| Forward Dividend & Yield | 1.45 (1.10%) |
| Ex-Dividend Date | Aug 15, 2024 |
| 1y Target Est | N/A |
ZacksNovo Nordisk (NVO) Gains As Market Dips: What You Should Know
Novo Nordisk (NVO) concluded the recent trading session at $132.06, signifying a +0.05% move from its prior day's close.
ReutersHims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month. For patients on a 12-month plan, Hims offers a semaglutide injection for $199 a month, according to its website. The news comes after U.S. Senator Bernie Sanders said multiple generic drugmakers confirmed they could sell custom-made versions of Novo's drug for less than $100 a month using the semaglutide.
- Yahoo Finance Video
Weight loss drug pricing under fire with pills on the horizon
Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical stocks like Novartis (NVS) and Novo Nordisk (NVO) as weight loss drug makers are set to meet with lawmakers like Senator Bernie Sanders to discuss pricing. Khemlani provides insight into the weight loss drug market and pricing in the US compared to other countries around the world. She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Naomi Buchanan.
